Pill vs. shot: new hope for preventing deadly clots in cancer patients
NCT ID NCT07270263
Summary
This study is testing if blood thinner pills (apixaban or rivaroxaban) are as safe and effective as standard daily shots (low-molecular-weight heparin) at preventing dangerous blood clots in people being treated for blood cancers like leukemia, lymphoma, or multiple myeloma. About 100 participants will be randomly assigned to receive one of the three treatments and followed for 6 months. The goal is to find a more convenient and patient-friendly way to prevent clots, which are a serious risk during cancer therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Department of Haematology & Transplantology
RECRUITINGGdansk, Pomeranian Voivodeship, 80-152, Poland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.